This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This MNDA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 26-53 amino acids from the N-terminal region of human MNDA.
MNDA
Reaktivität: Human
WB, IHC, ICC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
For FACS starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.26 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
The myeloid cell nuclear differentiation antigen (MNDA) is detected only in nuclei of cells of the granulocyte-monocyte lineage. A 200-amino acid region of human MNDA is strikingly similar to a region in the proteins encoded by a family of interferon-inducible mouse genes, designated Ifi-201, Ifi-202, and Ifi-203, that are not regulated in a cell- or tissue-specific fashion. The 1.8-kb MNDA mRNA, which contains an interferon-stimulated response element in the 5-prime untranslated region, was significantly upregulated in human monocytes exposed to interferon alpha. MNDA is located within 2,200 kb of FCER1A, APCS, CRP, and SPTA1. In its pattern of expression and/or regulation, MNDA resembles IFI16, suggesting that these genes participate in blood cell-specific responses to interferons.